[go: up one dir, main page]

MX2022011659A - Proteinas de union a antigeno que se unen a pd-l1. - Google Patents

Proteinas de union a antigeno que se unen a pd-l1.

Info

Publication number
MX2022011659A
MX2022011659A MX2022011659A MX2022011659A MX2022011659A MX 2022011659 A MX2022011659 A MX 2022011659A MX 2022011659 A MX2022011659 A MX 2022011659A MX 2022011659 A MX2022011659 A MX 2022011659A MX 2022011659 A MX2022011659 A MX 2022011659A
Authority
MX
Mexico
Prior art keywords
bind
antigen
binding proteins
manufactured
higher yields
Prior art date
Application number
MX2022011659A
Other languages
English (en)
Inventor
Heyue Zhou
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2022011659A publication Critical patent/MX2022011659A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan anticuerpos anti-PD-L1 de clase IgG que tienen una mejor capacidad para elaborarse con altos rendimiento. Más específicamente, se divulgan anticuerpos humanos que se unen a PD-L1, fragmentos de unión a PD-L1 que se pueden elaborar con altos niveles.
MX2022011659A 2016-01-29 2018-07-27 Proteinas de union a antigeno que se unen a pd-l1. MX2022011659A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29

Publications (1)

Publication Number Publication Date
MX2022011659A true MX2022011659A (es) 2022-10-13

Family

ID=59386438

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009228A MX2018009228A (es) 2016-01-29 2017-01-27 Proteínas de unión a antigeno que se unen a pd-l1.
MX2022011659A MX2022011659A (es) 2016-01-29 2018-07-27 Proteinas de union a antigeno que se unen a pd-l1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009228A MX2018009228A (es) 2016-01-29 2017-01-27 Proteínas de unión a antigeno que se unen a pd-l1.

Country Status (18)

Country Link
US (4) US10118963B2 (es)
EP (1) EP3408400B1 (es)
JP (3) JP6883590B2 (es)
KR (1) KR20190026642A (es)
CN (2) CN116333124A (es)
AU (1) AU2017212717B2 (es)
BR (1) BR112018015480A2 (es)
CA (1) CA3013051A1 (es)
CL (1) CL2018002034A1 (es)
EA (1) EA037855B1 (es)
ES (1) ES2986360T3 (es)
IL (1) IL260846B2 (es)
MX (2) MX2018009228A (es)
NZ (1) NZ745357A (es)
PH (1) PH12018501611A1 (es)
SG (1) SG11201806496SA (es)
TW (1) TWI760323B (es)
WO (1) WO2017132562A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014029883B1 (pt) 2012-05-31 2023-10-24 Sorrento Therapeutics Inc. Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2986360T3 (es) 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7430924B2 (ja) * 2018-03-22 2024-02-14 ケイレス アーゲー 拮抗的抗原結合タンパク質
KR102752624B1 (ko) * 2018-04-09 2025-01-13 오리진셀 테라퓨틱스 코포레이션, 엘티디. 항- pd-l1 항체 및 이의 용도
EP3818085A4 (en) * 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR TREATING A DISEASE OR CONDITION
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
KR20210046725A (ko) 2018-08-20 2021-04-28 1글로브 바이오메디칼 씨오., 엘티디. 신규 암 면역요법 항체 조성물
WO2020123543A2 (en) * 2018-12-11 2020-06-18 Sanford Burnham Prebys Medical Discovery Institute Models and methods useful for the treatment of serrated colorectal cancer
JP7538130B2 (ja) 2019-01-23 2024-08-21 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－ｌ１ダイアボディおよびその使用
CA3136453A1 (en) 2019-04-18 2020-10-22 Qlsf Biotherapeutics Inc. Humanized anti-pd-l1 antibodies
CN113795510A (zh) 2019-08-29 2021-12-14 荣昌生物制药(烟台)股份有限公司 抗pd-l1抗体及其应用
CN116323954A (zh) * 2020-06-26 2023-06-23 索伦托药业有限公司 表达免疫调节融合蛋白的溶瘤病毒
JP2023539369A (ja) 2020-09-02 2023-09-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 抗体－ナノ粒子複合体、ならびにその作製および使用方法
WO2022103242A1 (ko) 2020-11-16 2022-05-19 주식회사 이뮨온시아 면역항암제에 대한 치료 반응성을 예측하기 위한 바이오마커 및 이의 용도
BR112023023270A2 (pt) * 2021-05-07 2024-01-30 Immuneoncia Therapeutics Inc Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1
CA3221925A1 (en) 2021-06-09 2022-12-15 Sorrento Therapeutics, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
JP2025532635A (ja) * 2022-09-19 2025-10-01 ソノマ バイオセラピューティクス， インコーポレイテッド 制御性ｔ細胞を標的化して化膿性汗腺炎を治療するためのシトルリン化抗原特異的キメラ抗原受容体
IL322179A (en) 2023-01-30 2025-09-01 Kymab Ltd Antibodies
KR20250133603A (ko) * 2024-02-29 2025-09-08 주식회사유한양행 항-tigit/항-pd-l1 이중특이적 항체 및 이의 용도
KR20250165706A (ko) 2024-04-13 2025-11-27 주식회사 이뮨온시아 암 치료를 위한 pd-l1 저해제를 이용한 신보조요법
EP4656658A1 (en) 2024-04-13 2025-12-03 Immuneoncia Therapeutics, Inc. Neoadjuvant therapy using pd-l1 inhibitor for treating cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DK0651761T3 (da) 1992-07-13 2003-02-10 Bionebraska Inc Fremgangsmåde til modifikation af rekombinante polypeptider
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
KR102283639B1 (ko) 2007-06-01 2021-08-02 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BR112014029883B1 (pt) * 2012-05-31 2023-10-24 Sorrento Therapeutics Inc. Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
KR101947702B1 (ko) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
HK1221964A1 (zh) * 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1

Also Published As

Publication number Publication date
JP2021102633A (ja) 2021-07-15
TWI760323B (zh) 2022-04-11
US20190092861A1 (en) 2019-03-28
US11919952B2 (en) 2024-03-05
CN109715821B (zh) 2022-09-06
IL260846B2 (en) 2023-02-01
WO2017132562A8 (en) 2017-09-08
NZ745357A (en) 2025-08-29
EP3408400B1 (en) 2024-06-26
CN109715821A (zh) 2019-05-03
EP3408400A1 (en) 2018-12-05
BR112018015480A2 (pt) 2019-05-21
IL260846B (en) 2022-10-01
CL2018002034A1 (es) 2019-03-15
US20240190959A1 (en) 2024-06-13
KR20190026642A (ko) 2019-03-13
AU2017212717B2 (en) 2023-11-16
AU2017212717A1 (en) 2018-09-06
US10118963B2 (en) 2018-11-06
PH12018501611A1 (en) 2019-04-08
US20170218066A1 (en) 2017-08-03
US20210147539A1 (en) 2021-05-20
EA201891709A1 (ru) 2019-01-31
EA037855B1 (ru) 2021-05-27
WO2017132562A1 (en) 2017-08-03
EP3408400C0 (en) 2024-06-26
EP3408400A4 (en) 2019-11-27
JP2019507183A (ja) 2019-03-14
SG11201806496SA (en) 2018-08-30
JP7140867B2 (ja) 2022-09-21
JP6883590B2 (ja) 2021-06-09
MX2018009228A (es) 2019-07-08
US10919964B2 (en) 2021-02-16
JP2022095910A (ja) 2022-06-28
CN116333124A (zh) 2023-06-27
ES2986360T3 (es) 2024-11-11
CA3013051A1 (en) 2017-08-03
IL260846A (es) 2018-09-20
TW201736400A (zh) 2017-10-16

Similar Documents

Publication Publication Date Title
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
CY1123358T1 (el) Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CL2016002460A1 (es) Anticuerpos biespecíficos que se unen a cd38 y cd3
MX390385B (es) Anticuerpos anti-pd-l1.
EP3389699A4 (en) CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES TO HUMAN CTLA4 AND USES THEREOF
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
MX384025B (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MX388181B (es) Anticuerpos anti-pd-1.
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
CO2019013669A2 (es) Anticuerpos anti-garp-tgf-β
MX390190B (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
GT201400045A (es) Anticuerpo anti-abtcr
GEAP202114453A (en) Anti-lag3 antibodies and antigen-binding fragments
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201691321A1 (ru) Антитела и способы их применения
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EP3613770A4 (en) MONOCLONAL ANTIBODY AGAINST PD-L1
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
TN2019000161A1 (en) Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
EP3768724A4 (en) NEW ANTI-PD-1 ANTIBODIES